Evidence level: B
医疗免责声明:本文为研究性证据梳理,不构成任何诊断标准、治疗建议或临床决策依据。文中涉及的心功能评估必须由执业医师依据规范检查完成。任何自称”把脉即可测射血分数”的说法,本文不支持。
先回答一个直接的问题:有没有现成证据?
没有直接命中。 本轮在 PubMed 用四组关键词实测:
| 检索式 | 返回 |
|---|---|
pulse wave harmonic left ventricular ejection fraction |
6 条,全部是超声/瓣膜/血流动力学方向,无一涉及”脉搏谐波比值” |
photoplethysmography AND left ventricular ejection fraction |
有命中,但为波形形态/可穿戴方向 |
heart qi deficiency AND echocardiography |
命中为中药/针刺干预的心衰研究,非脉象-心功能定量对照 |
arterial waveform harmonic diastolic dysfunction echocardiography |
空列表 |
所以本课题(池③ #92)的处境是:“脉搏波参数 → 心功能”这一层有真实证据;”HRI-C2/C3 比值 → LVEF”这一层没有。
有证据的那一层:脉搏波参数确实与心功能相关
三条真实锚点(本轮 E-utilities 回查 title/期刊/首作者一致):
锚点 1|Kulin D. et al., Physiol Int 2025(PMID 40892475)
标题直译:”评估基于光电容积脉搏波的脉搏波参数与复合评分用于心功能评估——与……的比较”。这是最贴近本课题的一条:它做的正是”把 PPG 波形参数拿去做心功能评估”,且用了复合评分(composite score)而非单一指标——这与 C2/C3 是”比值”而非”绝对幅值”的思路同构。
锚点 2|Chang T.Y. et al., J Cardiol 2026(PMID 41176221)
“无接触远程光电容积脉搏波识别左室收缩功能不全型心衰的新应用”。这条的价值在于结局定义:它用的不是泛泛的”心衰”,而是按射血分数分型(HFrEF)——正是本课题要对齐的 LVEF 分型口径。
锚点 3|Stücker B. et al., Sci Rep 2026(PMID 42486909)
“无创 PPG 可穿戴胸贴用于运动中心输出量评估的可行性”。这条把范围推到心输出量(CO),比 LVEF 更进一步——提示 PPG 波形里携带的血流动力学信息不止一个维度。
反向对照|池③主线已有锚点(谐波侧):
– Lin S.K. et al., Sci Rep 2021(PMID 33903610)——动脉脉搏谱 + 多层感知机分类,证明脉搏谱本身有可分类信息
– Wu L.W. et al., Sci Rep 2022(PMID 36509825)——动脉脉搏谱区分肌少症/代谢综合征,证明谱特征可跨病种迁移
两层的接缝在哪:谐波侧有”谱可分类”的证据(池③主线);心功能侧有”PPG 参数可评估心功能”的证据(锚点 1/2)。但没有任何一篇把两侧用同一批受试者、同一时点、同一个统计模型连起来。
为什么这个接缝不能靠”看起来像”来缝合
一个常见的推论是:既然脉搏谐波反映血流动力学,而 LVEF 也是血流动力学指标,那 C2/C3 比值应该和 LVEF 相关。
这个推论有三个未验证的跳跃:
- 比值 vs 绝对量。C2/C3 是第二与第三谐波的比值。文献里验证过的是 PPG 波形参数(上升时间、反射指数、二次导数比等)与心功能的关系,不是”某两个谐波的比值”。比值这个操作会消掉什么、放大什么,没有先验答案。
- 时点对齐。LVEF 是超声当次测量的瞬时值;C2/C3 是脉搏采集窗内的平均。若两者采集间隔 > 10 分钟,血流动力学状态(体位、呼吸、情绪)可能已经漂移。
- 人群同质性。锚点 2 的研究人群是已确诊的心衰患者(结局明确、病理明确)。而中医心气虚人群是证候定义的人群,其中既有心功能正常者也有异常者——两者的基线分布不同,直接套用会引入”病例组合偏倚”。
这就是本课题真正的前置问题:不是”能不能建模型”,而是”在把两侧接起来之前,先证明接得上有意义“。
建模前必须过的四道关
| 关 | 要求 | 未通过的后果 |
|---|---|---|
| K1 时点同步 | C2/C3 采集与超声 LVEF 测量间隔 ≤ 10 min,且同一体位 | 相关性被状态漂移稀释,模型系数不可解释 |
| K2 量表-仪器双盲 | 脉象采集者不知超声结果;超声医师不知脉象分级 | 采集时的期望效应(脉象”读”出心衰)无法排除 |
| K3 分层入组 | 按 LVEF 三分层(保留 ≥50% / 中间 40–49% / 降低 <40%)各 ≥ 60 例 | 无法区分”模型在哪个亚组有效”,易被整体 AUC 掩盖 |
| K4 比值稳定性 | 同一受试者 C2/C3 复测 ICC ≥ 0.75(与池③ #21 二十八脉复测信度同口径) | 分母不稳,比值不可用,模型建在噪声上 |
K4 是门槛中的门槛。池③ #21 已经建立了脉象复测信度的方法学(ICC + 时间漂移模型),本课题应当直接复用那套口径,而不是另起一套。
本文不做什么
必须写清楚边界:
- 本文不给任何 AUC、敏感度、特异度数值。因为不存在可引用的实测结果——本课题尚未执行。
- 本文不建议把 C2/C3 当 LVEF 的替代品。锚点 1 用的复合评分、锚点 2 用的是分型识别,都不是”用波形反推一个连续数值”。
- 本文不把”中医心气虚 = 左室收缩功能不全”写成已证结论。两者是不同定义体系下的构念;构念收敛效度是待检验命题,不是前提。
- 任何面向患者的”把脉测心功能”表述,均在本课题的边界之外,且与本文的医疗免责声明冲突。
下一步(写入 backlog)
本课题的有效推进不是产出一篇”看起来有模型”的文章,而是:
- 把 K1–K4 写成实验设计的入组与质控章节(与 P3-EXP 系列同格式)
- 复用 #21 的复测信度口径做 K4 的样本量估算
- 若 K4 预实验(n=30 复测)ICC < 0.75 → 本课题降级为”比值不适用”的负结果,不再进入 K1–K3
核验锚点
| 编号 | PMID | 首作者 | 载体 | 年份 | 角色 |
|---|---|---|---|---|---|
| A1 | 40892475 | Kulin D. | Physiol Int | 2025 | PPG 脉搏波参数 + 复合评分评估心功能 |
| A2 | 41176221 | Chang T.Y. | J Cardiol | 2026 | rPPG 识别 HFrEF(按射血分数分型) |
| A3 | 42486909 | Stücker B. | Sci Rep | 2026 | PPG 胸贴评估心输出量 |
| A4 | 33903610 | Lin S.K. | Sci Rep | 2021 | 动脉脉搏谱 + MLP(谐波侧可分类) |
| A5 | 36509825 | Wu L.W. | Sci Rep | 2022 | 动脉脉搏谱跨病种迁移 |
核验方式:NCBI E-utilities esummary 逐条回查 title / 期刊 / 首作者一致。五条均为真实 PMID。
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
证据与局限
本文证据等级为 B,属 measurable,结论限于研究层面的推断,不构成对个体情形的判定。不构成任何诊断标准、治疗建议或临床决策依据**。
局限:本文未覆盖全部相关文献,效应量与结论随样本与方法变化;传统体系与现代研究的对照属结构类比而非等价证明,请结合专业判断参考。
Pre-requisites for a Combined Diagnostic Model Using Pulse Diagnosis Harmonics and Cardiac Ultrasound: C2/C3 Ratio × LVEF
Evidence level: B
Medical Disclaimer: This article serves as a review of research evidence and does not constitute any diagnostic criteria, treatment recommendations, or clinical decision-making basis. Cardiac function assessment must be completed by licensed practitioners according to standard protocols. Any claim suggesting “pulse diagnosis alone can measure ejection fraction” is not supported by this text.
Direct Answer: Is There Existing Evidence?
No direct evidence exists. In this round, we conducted a search using four keyword sets on PubMed:
| Search Query | Results |
|---|---|
pulse wave harmonic left ventricular ejection fraction |
6 results, all focused on ultrasound/valvular/hemodynamic directions, with none involving “pulse wave harmonic ratios” |
photoplethysmography AND left ventricular ejection fraction |
Hits found, but focused on waveform morphology/wearable directions |
heart qi deficiency AND echocardiography |
Hits related to TCM herbal/needle intervention studies for heart failure, not quantitative pulse-symptom vs. cardiac function comparisons |
arterial waveform harmonic diastolic dysfunction echocardiography |
Empty list |
Thus, the situation for this topic (Pool ③ #92) is: There is real evidence linking “pulse wave parameters → cardiac function”; however, there is no evidence for the specific link “HRI-C2/C3 ratio → LVEF”.
The Layer with Evidence: Pulse Wave Parameters Are Indeed Related to Cardiac Function
Three verified anchors (re-checked via E-utilities for title, journal, and first author consistency in this round):
Anchor 1|Kulin D. et al., Physiol Int 2025 (PMID 40892475)
Title translation: “Assessment of pulse wave parameters based on photoplethysmography and composite scores for cardiac function evaluation—comparison with…” This is the closest match to this topic: it utilizes PPG waveform parameters for cardiac function assessment and employs a composite score rather than a single metric—this aligns structurally with the approach of using C2/C3 as a “ratio” rather than an absolute amplitude.
Anchor 2|Chang T.Y. et al., J Cardiol 2026 (PMID 41176221)
“New application of contactless remote photoplethysmography for identifying left ventricular systolic dysfunction type heart failure.” The value here lies in the outcome definition: it does not use generic “heart failure” but rather stratifies by ejection fraction (HFrEF)—exactly the LVEF stratification standard this topic aims to align with.
Anchor 3|Stücker B. et al., Sci Rep 2026 (PMID 42486909)
“Feasibility of non-invasive PPG wearable chest patch for cardiac output assessment during exercise.” This extends the scope to cardiac output (CO), going beyond LVEF—suggesting hemodynamic information carried by PPG waveforms spans multiple dimensions.
Reverse Contrast|Existing Anchors in Pool ③ Mainline (Harmonic Side):
– Lin S.K. et al., Sci Rep 2021 (PMID 33903610) — Arterial pulse spectrum + Multi-Layer Perceptron classification, proving pulse spectra contain classifiable information
– Wu L.W. et al., Sci Rep 2022 (PMID 36509825) — Arterial pulse spectrum distinguishes sarcopenia/metabolic syndrome, proving spectral features can transfer across disease categories
Where the Gap Lies: The harmonic side has evidence that “spectra are classifiable” (Pool ③ mainline); the cardiac function side has evidence that “PPG parameters can assess cardiac function” (Anchor 1/2). However, no single study links both sides using the same cohort, at the same time point, with a unified statistical model.
Why This Gap Cannot Be Seamed by “Appearing Similar”
A common inference is: Since pulse harmonics reflect hemodynamics and LVEF is also a hemodynamic indicator, the C2/C3 ratio should correlate with LVEF.
This inference involves three unverified jumps:
- Ratio vs. Absolute Quantity. C2/C3 is the ratio of the second and third harmonics. Literature has validated PPG waveform parameters (rise time, reflection index, second derivative ratios, etc.) against cardiac function, not “the ratio of specific harmonics”. The operation of taking a ratio eliminates certain factors while amplifying others, with no prior answer.
- Time Alignment. LVEF is an instantaneous value measured via ultrasound at a specific moment; C2/C3 is an average within the pulse acquisition window. If the interval between measurements exceeds 10 minutes, hemodynamic states (posture, respiration, emotion) may drift.
- Population Homogeneity. The study population in Anchor 2 consists of confirmed heart failure patients (clear outcome, clear pathology). In contrast, the TCM “Heart Qi Deficiency” population is defined by syndrome patterns, containing individuals with both normal and abnormal cardiac function—their baseline distributions differ. Direct application would introduce “case-mix bias.”
This is the true prerequisite question for this topic: Not “Can we build a model,” but “Before connecting the two sides, first prove that the connection is meaningful.“
Four Gates to Pass Before Modeling
| Gate | Requirement | Consequence of Failure |
|---|---|---|
| K1 Time Synchronization | Interval between C2/C3 acquisition and ultrasound LVEF measurement ≤ 10 min, same posture | Correlation diluted by state drift; model coefficients become uninterpretable |
| K2 Double-Blind Scale-Instrument | Pulse acquirer unaware of ultrasound results; Ultrasound physician unaware of pulse grading | Expectation effects during acquisition (pulse “reading” heart failure) cannot be excluded |
| K3 Stratified Enrollment | Stratify by LVEF thirds (retain ≥50% / middle 40–49% / reduced <40%), each group ≥60 cases | Cannot distinguish “which subgroup the model works in”; easily masked by overall AUC |
| K4 Ratio Stability | Same subject C2/C3 re-test ICC ≥ 0.75 (consistent with reliability metrics in Pool ③ #21 for 28-pulse re-test) | Unstable denominator renders ratio unusable; model built on noise |
K4 is the threshold within thresholds. Pool ③ #21 has already established a methodology for pulse re-test reliability (ICC + time drift model); this topic should directly reuse that metric framework rather than establishing a new one.
What This Article Does Not Do
Boundaries must be clearly defined:
- This article provides no AUC, sensitivity, or specificity values. No measurable results exist to cite—this topic has not yet been executed.
- This article does not recommend treating C2/C3 as a substitute for LVEF. Anchor 1 uses composite scores; Anchor 2 uses stratification recognition; neither involves “inferring a continuous value from waveforms.”
- This article does not write “TCM Heart Qi Deficiency = Left Ventricular Systolic Dysfunction” as a proven conclusion. They are constructs under different definitional systems; construct convergence validity is a proposition to be tested, not a premise.
- Any patient-facing statement claiming “pulse diagnosis measures cardiac function” falls outside this topic’s scope and conflicts with the medical disclaimer above.
Next Steps (To Be Added to Backlog)
Effective progression for this topic is not producing an article that “appears to have a model,” but rather:
- Transform K1–K4 into enrollment and quality control chapters for experimental design (matching P3-EXP series format)
- Reuse the re-test reliability metrics from #21 for K4 sample size estimation
- If K4 pre-experiment (n=30 re-tests) yields ICC < 0.75 → Downgrade this topic to a negative result indicating “ratio inapplicability,” halting entry into K1–K3
Anchor Verification
| ID | PMID | First Author | Vehicle | Year | Role |
|---|---|---|---|---|---|
| A1 | 40892475 | Kulin D. | Physiol Int | 2025 | PPG pulse wave parameters + composite score for cardiac function |
| A2 | 41176221 | Chang T.Y. | J Cardiol | 2026 | rPPG identifies HFrEF (stratified by ejection fraction) |
| A3 | 42486909 | Stücker B. | Sci Rep | 2026 | PPG chest patch assesses cardiac output |
| A4 | 33903610 | Lin S.K. | Sci Rep | 2021 | Arterial pulse spectrum + MLP (harmonic side classifiable) |
| A5 | 36509825 | Wu L.W. | Sci Rep | 2022 | Arterial pulse spectrum cross-disease transfer |
Verification Method: NCBI E-utilities esummary to re-check title, journal, and first author for each entry. All five are valid PMIDs.
Leave a Reply